Skip to main content

Table 2 Immunohistochemistry patient data

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Protein Expression

No of patients (%)

p-value

ITP

IP

ERCC 1

 High

11 (50)

9 (42.9)

0.906

 Moderate

5 (22.7)

7 (33.3)

 

 Low

2 (9.1)

2 (9.5)

 

 None

4 (18.2)

3 (14.3)

 

COX 2

 High

7 (31.8)

5 (23.8)

0.342

 Moderate

5 (22.7)

7 (33.3)

 

 Low

4 (18.2)

7 (33.3)

 

 None

6 (27.3)

2 (9.5)

 

III beta tubulin

 High

11 (50)

9 (42.9)

0.425

 Moderate

8 (36.4)

5 (23.8)

 

 Low

3 (13.6)

6 (28.6)

 

 None

0 (0)

1 (4.8)

 

CD4

 High

0 (0)

0 (0)

0.768

 Moderate

3 (13.6)

4 (19)

 

 Low

6 (27.3)

7 (33.3)

 

 None

13 (59.1)

10 (47.6)

 

CD8

 High

1(4.5)

0 (0)

0.226

 Moderate

3 (13.6)

3 (14.3)

 

 Low

3 (13.6)

8 (38.1)

 

 None

15 (68.2)

10 (47.6)

 
  1. ITP Ifosfamide Paclitaxel Cisplatin, IP Ifosfamide Cisplatin